October 14, 2023 | Daily JAM |
Look for a big earnings test for regional banks and a feW clues about consumer goods, airlines, and autos. Last week ended with great earnings reports from Big Banks JPMorgan Chase (JPM), Wells Fargo (WFC) and Citigroup (C). Big Bank earnings continue this week with Bank of America (BAC) and Goldman Sachs (GS) reporting on Tuesday. But the important news for the financial sector will come from the dozens of earnings reports from regional banks.
July 12, 2021 | Daily JAM, Mid Term |
The Johnson & Johnson (JNJ) coronavirus vaccine has been linked to a rare side effect, the immune system disorder Guillain-Barré syndrome. Of 12.8 million J&J doses administered in the United States, there have been about 100 cases of Guillain-Barré syndrome, according to preliminary reports from the Centers for Disease Control and Prevention. The Food and Drug Administration plans to add a warning about Guillain-Barré to the J&J vaccine, The Washington Post has reported.
April 18, 2021 | Daily JAM |
Earnings season will accelerate this week with reports from Coke, Johnson and Johnson, Snap, and Netflix
January 26, 2021 | Daily JAM, Morning Briefing |
Johnson & Johnson (JNJ) said on its regular quarterly earnings call today, Tuesday January 26, that it expects to release data from its COVID-19 vaccine trials soon. Like next week soon.
January 12, 2021 | Daily JAM, Stock Alerts |
Johnson & Johnson (JNJ) said today, January 12, that the the company is in the “final stages” of analyzing the data from its 45,000-patient Phase 3 trial of the single-dose version of its vaccine. “We hope to have that information very soon,” CEO Alex Gorsky said at a panel at JPMorgan Chase’s annual health care conference.
October 13, 2020 | Daily JAM |
Johnson & Johnson (JNJ) has paused the large Phase 3 clinical trial of its coronavirus vaccine because of an unexplained illness in one participant in the trial, the company said on Monday. The company did not say whether the sick volunteer had received the...
September 8, 2020 | Daily JAM |
Clinical trials of a covid-19 vaccine being developed by AstraZeneca (AZN) and the University of Oxford have been put on hold pending a review of a “potentially unexplained illness,” the company said in a statement today. “This is a routine action which has to happen...
July 22, 2020 | Daily JAM, Stock Alerts, VXRT |
In case you needed a reminder that there's a coronavirus vaccine race going on, today Pfizer (PFE) and its partner BioNTech (BNTX) announced that they had signed a $2 billion deal with the U.S. government to provide 100 million doses of its coronavirus vaccine...
March 30, 2020 | Daily JAM |
Johnson & Johnson (JNJ) said today that it will begin human testing of its experimental vaccine for the coronavirus by September and that clinical data on its effects is expected before the end of the year. If the vaccine works well, the company said it could be...
March 11, 2020 | Daily JAM, Morning Briefing, Short Term, Volatility, You Might Have Missed |
As of 1:45 p.m. in New York the Standard & Poor's 500 is down 4.62% and the Dow Jones Industrial Average is off 5.13%. The NASDAQ Composite is lower by 4.40% and the Russell 2000 small cap index, with its heavy load of smaller U.S. oil producers, has lost 5.23%....
April 19, 2019 | Daily JAM |
On April 16, Johnson & Johnson beat Wall Street estimates by 6 cents a share. Revenue for the first quarter of 2019 climbed 0.1% to $20.02 billion, above the $19.55 billion projected by Wall Street.But the results really reflected the very different fortunes of the company’s stagnant consumer business and its strongly growing drug business.
April 16, 2017 | Daily JAM |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
